• FrÉdÉric Selle, Pierre-Etienne Heudel, Anne-Claire Hardy-Bessard, Astrid Pozet, Jerome Meunier, Laurence Gladieff, Jean-Pierre Lotz, Magali Provansal, Paule Augereau, Dominique Berton, Nathalie Bonichon-Lamichhane, Hubert Orfeuvre, Patricia Pautier, Elsa Kalbacher, Yousef Tazi, and Dominique Spaeth.
• Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France fselle@hopital-dcss.org.
• Anticancer Res. 2020 Jul 1; 40 (7): 3939-3945.

BackgroundTrabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.Patients And MethodsPatients with ROC after at least one platinum-based regimen received 1.1 mg/m2 trabectedin plus 30 mg/m2 PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)].ResultsRecurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups.ConclusionTrabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

30 keywords...

hide…